Careers • News • Contact us •
« The IRCM is a synergistic research center, a unique and collaborative place that accelerates innovation in researching, understanding, and treating diseases. »
To accelerate the understanding of diseases and identify treatments, the IRCM was born from the desire to make both basic and clinical research part of the same equation. Today, the Institute is home to over thirty world-renowned researchers and clinicians who are supported by a team of professionals and students, all mobilized by the same mission. Our work is part of a comprehensive research continuum whose goal is improving health.
Training the next generation of scientific researchers and sharing knowledge are deeply rooted in our DNA. Every year we welcome hundreds of the best students in the world in order to multiply our impact and contribute to excellence in science. These students join our research groups to take part in a tangible and formative experience that allows them to directly contribute to our research efforts.
Our constant goal is to turn our discoveries and knowledge into innovative solutions to benefit patients. To this end, we put a premium on bringing value to our research, whether by developing concrete medical applications or by sharing our knowledge with the greater scientific community.
The IRCM is a free-thinking institution where we cultivate independence and excellence. While scientific discoveries depend on many factors, we believe that independent research is a crucial component that brings observation and intuition together, accelerating the emergence of new knowledge.
Discoveries
In a study published in the journal eLife, the team of Mathieu Ferron, Director of the Research Unit in Molecular Physiology at the IRCM, unveiled an optimized version of the hormone that could be the basis for innovative therapies.
Discoveries
The work of the team led by Dr. Hua Gu is published in the prestigious scientific journal "Immunity". This massive work is the first to identify a family of protein ubiquitin ligases (CBLs) as a common molecular trait causing Lupus in humans; a groundbreaking advance that could pave the way to future therapies in this field.
© Montreal Clinical Research Institute, Année.All rights reserves. | Privacy policy | Terms of use | Web site by Agence Riposte